• NASH-related cirrhosis can result in the development of ascites• Human NASH patients show increased lymphatic vessel density in liver and induction of IL-13 pathway in hepatic LECs• Mice treated with oxLDL show increased hepatic LEC IL-13 production• oxLDL treatment of human LECs reduced PROX1 expression in vitro. The gene discussed is IL13; the disease is metabolic dysfunction-associated steatohepatitis.